Clinical trials: CONTROL Condition
Reflux Episodes
TLESR-impedance Study in Patients
The purpose of the study is to compare frequency and content of reflux episodes in patients with gastroesophageal reflux disease.
- Trial name
- NCT00743444
- Testing
- AZD3355
- Volunteers
- 27 people
- Sponsor
- AstraZeneca
Parkinson Disease
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
This study is to evaluate the effictiveness and safety of Ly03003 following intramuscular injections
- Trial name
- NCT04571164
- Testing
- LY03003(Rotigotine,extended-release microspheres)
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Luye Pharma Group Ltd.
Diabetic Foot Ulcer (DFU)
A Study to Evaluate Safety and Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer
The MARSYAS II study which will be conducted in patients with diabetic foot ulcer (DFU) consists of a Lead-In Phase for safety assessment of multiple doses of the biologic investigational medicinal product (IMP) APO-2 and of a…
- Trial name
- NCT04277598
- Testing
- APO-2
- Where
- 14 sites in Austria, Czechia and 2 more
- Volunteers
- 159 people
- Sponsor
- Aposcience AG
Hemorrhagic Stroke, Intracerebral Hemorrhage (ICH)
Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).
This is a randomized, placebo-controlled, subject and investigator-blinded study to evaluate efficacy, safety and tolerability of BAF312 in participants with intracerebral hemorrhage (ICH)
- Trial name
- NCT03338998
- Testing
- BAF312 solution, BAF312 tablet
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Venous Thromboembolism (VTE)
Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers
This study is researching an experimental drug called REGN7508 (called "study drug") and will consist of 2 parts: Part 1 and Part 2.
- Trial name
- ROXI-CAT-II (NCT07493304)
- Testing
- REGN7508, Apixaban
- Where
- 13 sites in United States, Bulgaria and 3 more
- Volunteers
- 1,600 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause
The purpose of the study is to investigate if NNC0519-0130 affects the blood levels of a birth control pill that contains the two hormones ethinylestradiol and levonorgestrel.
- Trial name
- NCT06513104
- Testing
- NNC0519-0130, Levonorgestrel + Ethinylestradiol, Paracetamol
- Where
- Germany
- Volunteers
- 47 people
- Sponsor
- Novo Nordisk A/S
Dementia With Lewy Bodies
Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study
This study seeks to evaluate the efficacy and safety of intepirdine (RVT-101) in patients with dementia with Lewy bodies.
- Trial name
- NCT02669433
- Testing
- RVT-101 35 mg, RVT-101 70 mg
- Where
- 65 sites in United States, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Axovant Sciences Ltd.
Moderate/Severe Asthma
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period
- Trial name
- NCT00785733
- Where
- 44 sites in Romania
- Volunteers
- 1,182 people
- Sponsor
- AstraZeneca
Migraine With Aura, Migraine Without Aura
Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache
The primary objective of this study is to evaluate the efficacy and safety of dronabinol MDI for the acute treatment of moderate to severe migraine headache.
- Trial name
- NCT00123201
- Testing
- Dronabinol MDI
- Where
- 29 sites in United States
- Sponsor
- Solvay Pharmaceuticals
Major Depressive Disorder
The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects
The Safety, Tolerability and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Male and Female Subjects
- Trial name
- NCT04591301
- Testing
- HEC113995 PA•H2O tablets
- Where
- China
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- emnergize (NCT07091630)
- Testing
- Empasiprubart IV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 160 people
- Sponsor
- argenx
Healthy Subjects, Cystic Fibrosis
A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
This Phase 1/2a study is a double-blinded (subject and Investigator), randomized, placebo-controlled, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple…
- Trial name
- NCT03647228
- Testing
- IONIS-ENaCRx
- Where
- 8 sites in Germany, United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Ionis Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2, Hypertension
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and hypertension.
- Trial name
- NCT01096667
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 194 people
- Sponsor
- Merck Sharp & Dohme LLC
Hidradenitis Suppurativa
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- RECHARGE-2 (NCT06840392)
- Testing
- Remibrutinib Dose A, Remibrutinib Dose B
- Where
- 129 sites in United States, Argentina and 17 more
- Volunteers
- 565 people
- Sponsor
- Novartis Pharmaceuticals
Aortic Valve Stenosis
ExCEED: CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis
This study will monitor the safety and valve performance of the Edwards CENTERA Transcatheter Heart Valve (THV) System in patients with symptomatic, severe, calcific aortic stenosis who are at intermediate operative risk for…
- Trial name
- NCT03517436
- Testing
- TAVR with CENTERA THV
- Where
- 23 sites in United States
- Volunteers
- 101 people
- Sponsor
- Edwards Lifesciences
Autoimmune Diseases
A Study of the Safety, Tolerability, Pharmacokinetics and Food Effect After Single and Multiple Ascending Oral Doses
This is a Phase I Healthy volunteer study with the primary objective to evaluate the safety and pharmacokinetics profile of AX-158. The first part will evaluate single ascending dose administrations.
- Trial name
- NCT05218434
- Testing
- AX-158
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Artax Biopharma Inc
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17
The purpose of this study is to assess the safety and efficacy of SPD503 (Guanfacine hydrochloride) compared to placebo in the treatment of ADHD in children and adolescents aged 6-17
- Trial name
- NCT00152009
- Testing
- SPD503 (Guanfacine hydrochloride) (2 mg), SPD503 (3 mg), SPD503 (4 mg)
- Volunteers
- 345 people
- Sponsor
- Shire
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis
This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the…
- Trial name
- NCT05424887
- Testing
- AK3280
- Where
- China
- Volunteers
- 105 people
- Sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.
Obesity
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity
The purpose of this study is to determine which of seven combinations of Zonisamide CR and Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of obesity not associated with the complications…
- Trial name
- NCT00339014
- Testing
- Zonisamide CR and Bupropion SR
- Where
- 15 sites in United States
- Volunteers
- 611 people
- Sponsor
- Orexigen Therapeutics, Inc
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.